Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

• Published in: Journal of gastrointestinal surgery Vol. 17; no. 9; pp. 1609 - 1617
• Main Authors: Kobayashi, Masanori, Sakabe, Tomoyo, Abe, Hirofumi, Tanii, Mitsugu, Takahashi, Hidenori, Chiba, Asako, Yanagida, Eri, Shibamoto, Yuta, Ogasawara, Masahiro, Tsujitani, Shun-ichi, Koido, Shigeo, Nagai, Kazuhiro, Shimodaira, Shigetaka, Okamoto, Masato, Yonemitsu, Yoshikazu, Suzuki, Noboru, Nagaya, Masaki
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.09.2013; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Antigens; Bile Duct Neoplasms - immunology; Bile Duct Neoplasms - mortality; Bile Duct Neoplasms - therapy; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms - immunology; Biliary Tract Neoplasms - mortality; Biliary Tract Neoplasms - therapy; Cancer therapies; Cancer Vaccines - therapeutic use; Chemotherapy; Cholangiocarcinoma - immunology; Cholangiocarcinoma - mortality; Cholangiocarcinoma - therapy; Clinical trials; Dendritic cells; Dendritic Cells - immunology; Female; Gallbladder Neoplasms - immunology; Gallbladder Neoplasms - mortality; Gallbladder Neoplasms - therapy; Gastroenterology; Hospitals; Humans; Immunotherapy; Immunotherapy, Active - methods; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Mucin-1 - immunology; Original Article; Peptides; Prostate cancer; Retrospective Studies; Surgery; Survival Analysis; Treatment Outcome; WT1 Proteins - immunology; United States > US; Japan; Dendritic cell; MUC1; WT1; Immunotherapy and biliary tract cancer
• ISSN: 1091-255X; 1873-4626
• DOI: 10.1007/s11605-013-2286-2

Background The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively ( P  = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively ( P  = 0.023). Conclusions Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.